Morgan Stanley Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $4.00

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price objective decreased by equities researchers at Morgan Stanley from $8.00 to $4.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s price objective points to a potential upside of 203.03% from the stock’s current price.

A number of other research analysts have also recently commented on ZNTL. Leerink Partners restated a “market perform” rating and set a $2.00 price target on shares of Zentalis Pharmaceuticals in a research note on Tuesday. Wall Street Zen lowered Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Tuesday. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $5.03.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $1.32 on Wednesday. The firm has a market cap of $95.37 million, a PE ratio of -0.64 and a beta of 1.87. The company has a 50-day moving average of $1.53 and a two-hundred day moving average of $1.45. Zentalis Pharmaceuticals has a 1-year low of $1.01 and a 1-year high of $4.16.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.12. Sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently bought and sold shares of ZNTL. Catalyst Funds Management Pty Ltd purchased a new position in Zentalis Pharmaceuticals during the second quarter worth about $31,000. Cerity Partners LLC raised its stake in shares of Zentalis Pharmaceuticals by 58.7% during the 1st quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock worth $33,000 after buying an additional 7,579 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in Zentalis Pharmaceuticals during the second quarter worth about $37,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $38,000. Finally, Corient Private Wealth LLC acquired a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at $41,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.